As the methods and approaches matured, so did the published content of the JBS.
After two decades of publishing, it became clear that the scope of JBS had changed. JBS was no longer just about higher-and-higher-throughput screening but had evolved to encompass all aspects of complex assay cascades (low-and medium-throughput; smarter, more efficient, and/or highercontent screening; target validation), the ingenious application of novel assay methods, and quantitative biology, and to elucidate mechanisms of action. The journal began to incorporate these newer aspects along with formal reviews on new drug discovery challenges and special issues on target biology. The latter change was instituted as it became clear that inadequate fundamental target knowledge led to screens being conducted that were not relevant to the physiological state and/or mechanism of action required to produce the desired biological consequence.
Along the way (circa 2010), the Association of Laboratory Automation (ALA) and the SBS merged to form a more integrated and cohesive global organization-the Society for Laboratory Automation and Screening (SLAS). By 2016, it was clear that new names for the journals representing the combined organization were required to reflect the new scope and unity of SLAS. In 2017, the Journal of Laboratory Automation became SLAS Technology, and the Journal of Biomolecular Screening was renamed SLAS Discovery.
The names have changed from SBS and ALA to SLAS, from JALA to SLAS Technology, and from JBS to SLAS Discovery. The journal content has broadened and the taglines have changed as well. So, what's in a name? From this editor's perspective, it is about identity and relevance. The community has made immense progress in drug discovery, thanks at least in part to the immense contributions of SLAS members. At SLAS Discovery, we will continue to encourage change and innovation. We started as a "society of screeners" and have since applied and shared our learnings on rigor and depth of thinking to impact the broader success of drug discovery. SLAS Discovery will continue to embrace screening as a fundamental component of its content, but it has evolved to be so much more-to truly advance the science of drug discovery! Please see our scope statement for more detail: journals.sagepub.com/aims-scope/JBX.
If you have any concerns or further suggestions for change, please feel free to contact me at EditorCampbell@ slas.org. 
